MedTrace Logo

Acute Dose-dependent Effects of DMT in Healthy Subjects

NCT05384678 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-04-25

No results posted yet for this study

Summary

N,N-dimethyltryptamine (DMT) is a psychoactive substance with similar effects such as LSD or psilocybin. However, DMT is less well characterized than the latter substances. The present study is a modern randomized cross-over trial, investigating different continuous intravenous DMT dose rates over a broad dose range. Thus, different doses will be tested and related to subjective and autonomic effects.

Conditions

  • Healthy

Interventions

DRUG

N,N-Dimethyltryptamine (54 mg)

A dose rate of 0.6 mg/min will be administered

DRUG

N,N-Dimethyltryptamine (108 mg)

A dose rate of 1.2 mg/min will be administered

DRUG

N,N-Dimethyltryptamine (162 mg)

A dose rate of 1.8 mg/min will be administered

DRUG

N,N-Dimethyltryptamine (216 mg)

A dose rate of 2.4 mg/min will be administered

DRUG

Placebo

A Placebo (saline infusion) will be administered.

DRUG

N,N-Dimethyltryptamine (108 mg) + dose titration

A dose rate of 1.2 mg/min will be administered with subsequent patient-guided dose titration

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · University Hospital Basel, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2024-03-08
Completion
2024-03-13

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05384678 on ClinicalTrials.gov